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Background: Atrial fibrillation (AF) is the most common sustained arrhythmia. It occurs 
in 1%–2% of the general population and its prevalence increases with age. Dronedarone, a 
  noniodinated benzofuran similar to amiodarone, was developed as an antiarrhythmic agent 
for patients with atrial fibrillation. The aim of our systematic review was to critically evaluate 
randomized controlled trials that compared treatment with dronedarone versus placebo or 
amiodarone in patients with atrial fibrillation.
Methods: Electronic databases (MEDLINE, Embase, and Central) were searched up to 
November 2011 with no language restrictions. We included randomized controlled trials in 
which dronedarone was compared to placebo or other drugs in patients with AF. Internal and 
external validity was assessed.
Results: We identified seven papers corresponding to eight randomized controlled trials. The 
DAFNE, EURIDIS/ADONIS, and ATHENA trials demonstrated a reduction of AF recurrence 
with dronedarone as compared to placebo in patients with nonpermanent AF. The DIONYSOS 
study showed that dronedarone is less effective for the prevention of recurrent AF but improved 
tolerability as compared to amiodarone. Considering patients with permanent AF, the ERATO 
trial showed that dronedarone had rate-control effects while the PALLAS study was stopped 
early since stroke, myocardial infarction, systemic embolism, or death from cardiovascular 
causes were significantly more frequent in subjects treated with dronedarone as compared to 
placebo. The ANDROMEDA trial included patients with recent hospitalization for heart failure 
and was terminated early because of excess of deaths in the dronedarone group.
Conclusion: Like most antiarrhythmic drugs, dronedarone reduces the recurrence of AF in 
patients with paroxysmal or persistent AF as compared to placebo. However, relapse rates 
in the first year of therapy are high. Moreover, dronedarone showed to be less effective than 
amiodarone. Finally, dronedarone should be avoided in patients with permanent AF and a high 
risk for cardiovascular events or severe congestive heart failure.
Keywords: amiodarone, arrhythmia, cardiovascular events
Introduction
A 68-year-old man presented to the emergency department for a sudden onset of 
palpitation, fatigue, and dyspnea on exertion. FC was the medical doctor on duty. The 
patient denied chest pain and reported a long-standing history of hypertension, but 
there was no history of coronary artery disease and no other cardiovascular risk factors. 
Home medications were bisoprolol (5 mg daily) and enalapril (20 mg daily).
Twelve lead-ECG showed atrial fibrillation (AF) with a ventricular rate of 160 bpm; 
blood tests were unremarkable. The patient was treated with intravenous propafenone 
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with successful cardioversion to sinus rhythm. Considering 
the risk factors for   cardioembolic stroke (hypertension and 
age determining a CHA2D2-VASC score of 2 points),1 oral 
anticoagulant therapy was started.
Over the previous months the patient had had two 
emergency department visits for palpitation and dyspnea 
on exertion due to AF with high ventricular rate; in both 
cases he had spontaneous cardioversion to sinus rhythm in 
the emergency department. After the first episode of AF, a 
transthoracic echocardiogram was performed that showed 
moderate increased left ventricular wall thickness (16 mm), 
normal left ventricular and atrial sizes, and normal systolic 
function. Thyroid function tests were normal.
Considering the disabling symptoms during the 
recurrences of AF and the inability to attain adequate 
rate control, FC decided to adopt a rhythm control strat-
egy for the maintenance of sinus rhythm. Which antiar-
rhythmic treatment should be started in a patient with AF 
and left ventricular hypertrophy without coronary artery 
disease?
In order to choose the appropriate therapy, FC decided 
to look at two of the most authoritative clinical guidelines 
on the topic, edited respectively by the American College 
of Cardiology Foundation/American Heart Association 
(ACCF/AHA)2,3 and by the European Society of Cardiology 
(ESC).4 As the recommendations were discordant, FC was 
puzzled. In fact, while ACCF/AHA suggested amiodarone 
as first-line treatment in this clinical setting, ESC guidelines 
recommended dronedarone (Table 1).
So, FC wondered: “Was dronedarone actually useful 
to maintain sinus rhythm? Compared to amiodarone, was 
dronedarone more efficacious and safe? What was the 
  available evidence? Did any study evaluate clinical relevant 
end points such as mortality?”
AF is the most common sustained arrhythmia. It occurs 
in 1%–2% of the general population and its prevalence 
increases with age.5,6 It may cause disabling symptoms, with 
impairment of both functional status and quality of life.
The ACC/AHA2,3 and ESC4 guidelines distinguish 
four types of AF: (1) “first detected or diagnosed”, 
(2) paroxysmal, (3) persistent, and (4) permanent AF. 
“First detected or   diagnosed AF” is AF identified for the 
first time,   independently of its duration or the presence of 
symptoms. Paroxysmal AF is defined as recurrent AF that 
terminates spontaneously in less than 7 days, usually in less 
than 48 hours. Persistent AF is AF lasting longer than 7 days 
or requiring pharmacological or electrical cardioversion 
to sinus rhythm. Finally, permanent AF lasts more than 
1 year. Moreover, into the category of persistent AF, ESC 
distinguishes a “long-standing persistent AF” with 1 year 
or more of duration after the adoption of a rhythm-control 
strategy. For permanent AF, on the contrary, rhythm-control 
strategy is not pursued.
AF is associated with increased morbidity and mortal-
ity, mainly due to stroke and heart failure.7,8
Management of AF patients is focused on reducing 
  symptoms and preventing the complications associated with 
arrhythmia. Two therapeutic strategies can be identified: a 
“rhythm-control” option, when antiarrhythmic drugs, with 
or without electrical cardioversion, are used to restore sinus 
rhythm, and a “rate-control” strategy, the main objective of 
which is to control ventricular response rate. In addition, 
stroke prophylaxis therapy is required in most AF patients 
and antithrombotic therapy is prescribed according to stroke 
risk stratification schemes, such as CHA2D2-VASC,1 taking 
into account also the patient’s risk of bleeding.
To date, randomized controlled trials have failed to dem-
onstrate the superiority of one strategy over the other.9–11 
Table 1 Choice of antiarrhythmic drug according to underlying pathology: comparison of ACCF/AHA2,3 and ESC4 guidelines
Underlying pathology ACCF/AHA ESC
Minimal or no heart disease Dronedarone flecainide propafenone sotalol Dronedarone flecainide propafenone sotalol
Hypertension
with LvH Amiodarone Dronedarone
without LvH Dronedarone flecainide propafenone sotalol Dronedarone flecainide propafenone sotalol
CAD Dronedarone sotalol dofetilide Dronedarone sotalol
Heart failure
Stable NYHA I/II Amiodarone dofetilide Dronedarone
NYHA III/Iv or unstable NYHA II Amiodarone dofetilide Amiodarone
Notes: In the congestive heart failure category, ACCF/AHA has two different subcategories: stable NYHA I/II and NYHA III/IV or unstable NYHA II. Unstable is defined as 
cardiac decompensation within the prior 4 weeks.
Abbreviations:  ACCF/AHA,  American  College  of  Cardiology  Foundation/American  Heart  Association;  ESC,  European  Society  of  Cardiology;  LvH,  left  ventricular 
hypertrophy; CAD, coronary artery disease; NYHA, New York Heart Association.
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Many drugs have been employed as antiarrhythmic options: 
amiodarone seems to be the most effective in preventing 
recurrences of AF,12,13 but its use is limited by toxicity.14
Dronedarone, a noniodinated benzofuran similar to 
amiodarone, was developed as an antiarrhythmic agent 
for patients with AF. Because of the structural differences 
between amiodarone and dronedarone, particularly the 
  deletion of iodine molecules, dronedarone has been supposed 
to have similar efficacy to amiodarone but fewer thyroid and 
pulmonary side effects.
This systematic review looked at the randomized controlled 
trials (RCTs) conducted to date that compared treatment with 
dronedarone versus placebo or amiodarone in patients with 
AF. Our aim was to assess the efficacy and side-effects of 
dronedarone and to critically evaluate current evidence.
Methods
Eligibility criteria
A bibliographic search was performed starting from the 
acronym PICOS (Patients or target population included in the 
trials, Intervention and Comparison, Outcome(s) assessed, 
type of Studies selected), suggested for formulating relevant 
and precise questions that can be answered through research 
and literature sources.15 It was decided to look for only RCTs, 
as they are considered to be at the first level of evidence in 
determining the benefits of a treatment.16
PICOS was defined in the following way:
•	 Types of patients: Participants of any age and gender 
affected by AF;
•	 Types of intervention and comparison: dronedarone at 
any dose versus placebo or other antiarrhythmic drug;
•	 Types of outcome measures: No restriction. Our aim 
was to exhaustively evaluate dronedarone’s efficacy and 
safety;
•	 Types of study: RCT.
Information sources and search criteria
RCTs were identified by searching electronic databases (Embase, 
PubMed, and Central). No limit was applied for   language or for 
year of publication of the studies. The   following search terms 
to search all trial registers and databases were used: “atrial 
fibrillation” (participants), “dronedarone” OR “amiodarone/
analogs and derivatives” OR “SR33589” (intervention/control), 
“randomized controlled trials” (type of study). The last search 
was run on November 25, 2011. In addition, the reference lists 
of retrieved studies, recent guidelines, meta-analyses, and other 
reviews of AF were checked.
Study selection
Eligibility assessment was performed independently in 
a blinded standardized manner by two reviewers (FD, 
ES).   Disagreements between reviewers were resolved by 
consensus, eventually involving a third reviewer (LT).
Data collection process and data items
For randomized trials a data extraction sheet was developed. 
Couples of authors (LT and ES, FC and FD, GMP, and GC) 
independently extracted the information from included studies. 
Disagreements were resolved by discussion between the two 
reviewers; if no agreement could be reached, it was planned that 
a third author (GC or GMP) would resolve controversies.
From each included trial we extracted information regarding: 
(1) the characteristics of the trial’s participants, with particular 
attention to the percentage of patients with AF at enrollment 
and inclusion and exclusion criteria in the trial; (2) type of inter-
ventions used (dose, duration, and frequency of dronedarone, 
characteristics of placebo or other antiarrhythmic drugs or 
registration that no treatment was given as control); (3) type of 
outcome measures (including length of follow-up and type of 
analysis, ie, “intention to treat” or “per protocol”).
Internal validity – risk of bias
In order to evaluate the internal validity of the RCTs 
included, risk of bias was assessed in the following items: 
(1) generation of allocation sequence; (2) appropriateness of 
allocation concealment; (3) completeness of outcomes data 
and (4) outcomes reporting. They were classified as adequate 
(low risk of bias), inadequate (high risk of bias), or unclear (if 
no information was reported), following the criteria specified 
in The Cochrane Handbook of Review of Interventions.17 Two 
reviewers (ES, LT) independently assessed trials according 
to the predefined quality criteria. Any disagreement was 
resolved by consulting a third party (GMP).
External validity of the evidence – 
directness
Reliable judgments about the external validity of RCTs 
are essential if treatments are to be used correctly in as 
many patients as possible in routine clinical practice. The 
Grading of Recommendations Assessment, Development 
and Evaluation Working Group, in the rating of the quality of 
evidence, refers to this aspect as the directness/indirectness 
of evidence. Directly quoting: “direct evidence comes from 
research that directly compares the interventions in which 
we are interested when applied to the populations in which 
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we are interested and measures outcomes important to 
patients”.18
For each study retrieved, it was decided to analyze the 
level of directness/indirectness and the external validity 
of the evidence evaluating some of the items proposed 
by   Rothwell.19 Mostly: (1) the differences between the 
population in the usual clinical setting (general medicine or 
cardiology division) and those that participated in the study, 
paying attention to the inclusion and exclusion criteria of the 
patients and those effectively included in the trial; (2) the 
differences between the interventions (experimental and 
comparison) in the study and those used in current practice, 
such as the type and the dose of the comparator drug and 
the limitations on the use of nontrial treatments (co-therapy); 
(3) the problems in outcome measures, as in the utilization of 
“surrogate” outcomes or, in the case of the use of composite 
outcomes, the risk linked to every component of the outcome; 
(4) the adequacy of the length of the follow-up in the trial.
Results
Study selection
Figure 1 presents a flow diagram to summarize the 
study selection process. Our literature search identified 
300 references; among these there were no duplicates. Two 
hundred and eighty-eight records were excluded on the basis 
of titles and abstracts, twelve of these citations proved to be 
eligible for inclusion and their full texts were analysed in 
more detail. Finally, we excluded five studies because they 
were post hoc analyses of eligible studies and included seven 
papers corresponding to eight RCTs.20–26
Study characteristics
The main features of the trials included are summarized in 
Table 2. Table 3 reports the principal characteristics of the 
participants in each trial.
We decided to group the studies according to clinical 
setting:
1.  RCTs including patients with nonpermanent AF (parox-
ysmal or persistent);
2.  RCTs including patients with permanent AF;
3.  RCTs considering patients with heart failure.
Only one study was designed to compare dronedarone and 
amiodarone for the maintenance of sinus rhythm in patients 
with nonpermanent AF.23
Figure 2 gives a summary of the risk of bias for each 
study. The overall quality of the evidence from the trials, 
Records identified through
database searching
(n = 218)
Records after duplicates removed
(n = 300)
Full-text articles assessed
for eligibility
(n = 12)
Papers included in the review
(n = 7)
corresponding to 8 studies
Full-text articles excluded
(n = 5)
because post-hoc analysis
Records excluded on
the base of titles and
abstracts
(n = 288)
Additional records identified
through other sources
(n = 82)
Figure 1 Flow of information search.
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with particular reference to the directness of the evidence 
produced, is reported for each study.
RCTs including patients  
in nonpermanent AF
DAFNE
The Dronedarone Atrial FibrillatioN study after Electrical 
Cardioversion (DAFNE) was a phase II randomized, dose-
ranging study comparing three doses of dronedarone (800, 
1200, and 1600 mg daily) versus placebo in patients with 
persistent AF (Tables 2 and 3).20
In this multicentric study 270 subjects with persistent 
AF and for whom cardioversion and antiarrhythmic therapy 
was warranted were randomized to receive 800, 1200, or 
1600 mg daily doses of dronedarone or placebo. The main 
analysis was conducted on 151 and 48 patients taking 
dronedarone and placebo, respectively, after successful 
pharmacological or electrical cardioversion. Treatment was 
continued for 6 months. The primary outcome was time to 
first AF   recurrence; heart rate in case of AF recurrences, the 
incidence of side effects and premature study drug discon-
tinuation were secondary end points.
Considering only patients receiving 800 mg of 
dronedarone daily (N = 54) and placebo (N = 48), time 
to first recurrence of AF was significantly increased in 
the dronedarone group (median time of 60 days versus 
5.3 days in the placebo arm, relative risk reduction 55%, 
95% confidence interval (CI) 28–72, P = 0.001; Table 4). 
Table 2 Principal characteristics of studies included
Trial name No of patients 
(D/C)
Dose Inclusion criteria Relevant exclusion  
criteria
Mean 
follow-up
DAFNE20,§ 102  
(54/48)
400 mg bid vs placebo Persistent AF NYHA III–Iv; QT . 500 ms;  
LvEF , 35%; use of other 
antiarrhythmic drugs; ICD
6 months
EURIDIS/ 
ADONIS21
1237  
(828/409)
400 mg bid vs placebo At least one episode of AF in  
the last 3 months; in sinus  
rhythm for at least 1 hour  
before randomization
Permanent AF;  
HR , 50 beats/min;  
NYHA III–Iv;  
creatinine . 1.7;  
use of class I–III  
antiarrhythmic drugs
12 months
ATHENA22 4628  
(2301/2327)
400 mg bid vs placebo Paroxysmal or persistent  
AF or atrial flutter and at least  
one cardiovascular risk factor  
(age . 70 years, hypertension  
needing at least two drugs,  
diabetes, previous stroke,  
transient ischemic attack or  
systemic embolism, left atrial  
diameter . 50 mm, LvEF , 40%)
Permanent AF;  
HR , 50 beats/min;  
NYHA Iv; GFR , 10 mL/min
21 months
DIONYSOS23 504  
(249/255)
400 mg bid vs  
amiodarone 600 mg/day 
for 28 days and  
then 200 mg/day  
for 6 months
Persistent or permanent AF  
(.72 hours)
Paroxysmal AF;  
QT . 500 ms; NYHA III–Iv;  
use of class I–III antiarrhythmic  
drugs; previous chronic  
treatment with amiodarone
6 months*
ERATO24 174  
(85/89)
400 mg bid vs placebo Permanent AF (.6 months) NYHA III–Iv; use of other  
antiarrhythmic drugs
6 months
PALLAS25 3236  
(1619/1617)
400 mg bid vs placebo Permanent AF or atrial flutter  
(.6 months); age . 65 years  
with additional cardiovascular risk  
factors (coronary artery disease,  
symptomatic heart failure,  
LvEF , 40%, or a combination of  
age . 70, hypertension, and diabetes)
Non-permanent AF;  
HR , 50 beats/min;  
QT . 500 ms; ICD
3.5 months
ANDROMEDA26 627  
(310/317)
400 mg bid vs placebo Patients hospitalized with worsening 
CHF (NYHA class III or Iv)
HR , 50 beats/min;  
QT . 500 ms; use of class I–III  
antiarrhythmic drugs
2 months†
Notes: §Only the placebo and dronedarone 800 mg daily arms were considered; †median follow-up; *follow-up duration from 6 months to 22 months.
Abbreviations:  D/C,  dronedarone/control;  AF,  atrial  fibrillation;  NYHA,  New  York  Heart  Association;  HR,  heart  rate;  LVEF,  left  ventricular  ejection  fraction;   
GFR, glomerular filtration rate; CHF, congestive heart failure; ICD, international cardioverter-defibrillator.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
469
Dronedarone in the management of atrial fibrillationInternational Journal of General Medicine 2012:5
Figure 2 Risk of bias assessment of the RCT included in the review. Legend: green 
(+), low risk of bias; yellow (?), unknown risk of bias.
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Dronedarone was shown to reduce ventricular rate on 
recurrences of AF in a   dose-dependent fashion (P = 0.0001, 
value across all doses) indicating some rate-control action. 
No proarrhythmic effect was reported and no evidence of 
thyroid, hepatic, neurologic or pulmonary complications 
was found (Table 5).
Overall quality of the evidence
The overall risk of bias could not be completely evaluated 
as much of the information about the methodology was 
not reported (Figure 2). DAFNE shows that dronedarone 
may be useful for the maintenance of sinus rhythm after 
  cardioversion. However, several limitations may weaken the 
quality of the evidence. First of all, none of the end points of 
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the study can be considered clinically relevant or hard end 
points. Secondly, no data was reported on the incidence of 
symptomatic AF recurrences, an important issue for patients 
in rhythm-control strategy. Furthermore, the results of the 
study were not described in detail as the data of the “intention 
to treat analysis” on all randomized patients was not shown. 
Finally, the limited sample size and the short follow-up might 
have underestimated side effects.
EURIDIS/ADONIS
The European Trial in Atrial Fibrillation or Flutter Patients 
Receiving Dronedarone for the Maintenance of Sinus 
Rhythm (EURIDIS) and the American-Australian Trial with 
Dronedarone in Atrial Fibrillation or Flutter Patients for the 
Maintenance of Sinus Rhythm (ADONIS) studies were two 
phase III, double-blind, randomized trials with the same 
protocol, that assessed the efficacy of 400 mg of dronedarone 
Table 4 Efficacy end points in dronedarone randomized controlled trials
Trial name Efficacy end points Drodenarone Control HR (95% CI) P
DAFNE20,§ Time to first recurrence (median of the days) 60 5.3 Not applicable 0.001
EURIDIS/ADONIS21 Time to first recurrence (median of the days) 116 53 Not applicable Not reported
Recurrence of atrial fibrillation up to 12 months (%) 64.1% 75.2% 0.75 (0.65–0.87) ,0.0001
ATHENA22 First hospitalization due to cardiovascular events or  
death from any cause before hospitalization – N (%)
734 (32%) 917 (39%) 0.76 (0.69–0.84) ,0.001
Death from any cause – N (%) 116 (5%) 139 (6%) 0.84 (0.66–1.08) 0.18
Death from cardiovascular cause – N (%) 63 (3%) 90 (4%) 0.71 (0.51–0.98) 0.03
First hospitalization due to cardiovascular events – N (%) 675 (29%) 859 (37%) 0.74 (0.67–0.82) ,0.001
DIONYSOS23 First AF recurrence or premature drug discontinuation  
for intolerance or lack of efficacy (efficacy primary  
end point) – N (%)
187 (75%) 150 (59%) 1.59 (1.28–1.98) ,0.0001
ERATO24 Change in mean ventricular rate at the day 14 day  
(beats/min)
–11 +0.7 Not applicable ,0.0001
PALLAS25 Stroke, myocardial infarction, systemic embolism,  
or death from cardiovascular causes – N (%)
43 (3%) 19 (1%) 2.29 (1.34–3.94) 0.002
Unplanned hospitalization for a cardiovascular cause  
or death – N (%)
127 (8%) 67 (4%) 1.95 (1.45–2.62) ,0.001
Death for cardiovascular causes – N (%) 21 (1%) 10 (0.6%) 2.11 (1.00–4.49) 0.046
Death for any cause – N (%) 25 (1%) 13 (0.6%) 1.94 (0.99–3.79) 0.049
Stroke – N (%) 23 (1%) 10 (0.6%) 2.32 (1.11–4.48) 0.02
Hospitalization for heart failure – N (%) 43 (3%) 24 (1%) 1.81 (1.10–2.99) 0.02
ANDROMEDA26 Death from any cause or hospitalization for  
worsening heart failure – N (%)
53 (17%) 40 (13%) 1.38 (0.92–2.09) 0.12
Death from all causes – N (%) 25 (8%) 12 (4%) 2.13 (1.07–4.25) 0.03
Hospitalization due to acute cardiovascular  
causes – N (%)
71 (23%) 50 (16%) Not reported 0.02
Hospitalization for worsening heart failure – N (%) 35 (11%) 30 (10%) Not reported Not reported
Death from arrhythmia or sudden death – N (%) 10 (3.2%) 6 (1.9%) Not reported NS
Notes: §Only the placebo and dronedarone 800 mg daily arms were considered.
Abbreviations: HR, hazard ratio; CI, confidence interval; AF, atrial fibrillation; NS, not significant.
Table 5 Combined main adverse events in dronedarone randomized controlled trials
Dronedarone versus  
placebo
Dronedarone versus amiodarone
Dronedarone N/total  
(%)
Placebo N/total  
(%)
Dronedarone N/total  
(%)
Amiodarone N/total 
(%)
Death 175/5209 (3.3%) 167/4835 (3.4%) 2/249 (0.8%) 5/255 (2.0%)
Pulmonary events# 362/2752 (13.1%) 357/2795 (12.8%) 0/249 0/255
Dysthyroidism 136/3158 (4.3%) 95/2763 (3.4%) 2/249 (0.8%) 15/255 (5.9%)
Bradyarrhythmia 170/4733 (3.6%) 55/4331 (1.3%) 47/249 (18.9%) 74/255 (29.0%)
Heart failure§ 94/2823 (3.3%) 54/2343 (2.3%) 16/249 (6.4%) 19/255 (7.4%)
Gastrointestinal events 370/2752 (13.4%) 236/2795 (8.4%) 32/249 (12.8%) 13/255 (5.1%)
Liver toxicity 173/4793 (3.6%) 98/4403 (2.2%) 30/249 (12.0%) 27/255 (10.6%)
Increased creatinine levels 185/5043 (3.7%) 43/4648 (0.9%) Outcome not considered Outcome not considered
Notes: #Cough and dyspnea were included; §according to the definition of the authors of the trial.
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twice a day in maintaining sinus rhythm in patients with an 
history of nonpermanent AF or flutter21 (Tables 2 and 3). 
EURIDIS was performed in 12 European countries, while 
ADONIS was performed in the United States of America, 
Canada, Argentina, Australia, and South Africa. The two 
studies enrolled a total of 1237 patients with paroxysmal or 
persistent AF or flutter; patients were randomized to drone-
darone (N = 828) or placebo (N = 409). New York Heart 
Association (NYHA) class III or IV congestive heart failure 
patients were excluded. The primary outcome was the time 
to the first documented AF relapse. The main secondary end 
points were symptoms related to AF and the mean ventricular 
rate during the first recurrence.
Combined results from the two studies are reported 
in Tables 4 and 5. In the 12-month follow-up period, the 
two trials showed a longer time to recurrence of the first 
AF/atrial flutter in the dronedarone group (median time to 
first   recurrence 116 versus 53 days in the placebo group, 
P-value not reported) and a lower AF recurrence rate up 
to 12 months (hazard ratio (HR) 0.75, 95% CI 0.65–0.87, 
P , 0.001). Dronedarone also significantly reduced the 
incidence of symptomatic first recurrence (37.7% versus 
46.0%; P , 0.01) and was well tolerated: among all the side 
effects only serum creatinine levels were significantly higher 
in the dronedarone group (2.4% versus 0.2%, P = 0.004).
Overall quality of the evidence
The risk of bias was low for the random sequence genera-
tion procedure as the risk of attrition bias (Figure 2). No 
information was reported for the other items. The population 
included can be considered representative of the patients 
usually referring to internal medicine or cardiology divi-
sions. EURIDIS/ADONIS demonstrates that dronedarone 
could have rhythm- and rate-control properties in patients 
with paroxysmal or persistent AF. However, the outcomes of 
the trial were not clinically relevant. Moreover dronedarone 
should have been compared with another antiarrhythmic drug 
instead of placebo. It is unclear what proportion of patients 
in the two groups had previously received and discontinued a 
treatment with amiodarone just before the enrollment: consid-
ering amiodarone’s long half-life, this could be a confounding 
factor, at least in the initial stages of the trial.
ATHENA
A Placebo-Controlled, Double-Blind, Parallel Arm Trial 
to Assess the Efficacy of Dronedarone 400 mg bid for the 
Prevention of Cardiovascular Hospitalization or Death from 
Any Cause in Patients with Atrial Fibrillation/Atrial Flutter 
(ATHENA) was a phase III trial that evaluated the effect 
of 400 mg of dronedarone twice a day versus placebo in 
4628 patients with paroxysmal or persistent AF or flutter 
who had additional risk factors for a major cardiovascular 
event (Tables 2 and 3).22 People were excluded if affected by 
NYHA class IV congestive heart failure and were enrolled 
while in sinus rhythm (after cardioversion) or in AF or flut-
ter but subsequently cardioverted. During the course of the 
trial the inclusion criteria were changed due to a mortality 
rate lower than expected, so that people were required to be 
aged 75 years or older to be eligible, or aged between 70 and 
75 years with at least one of the specified risk factors, while 
people younger than 70 years of age were excluded.
The primary end point was the first unplanned hospital-
ization due to cardiovascular events or death from any cause 
before admission to the hospital and hospitalization was 
defined as admission with at least an overnight stay in the 
hospital. Secondary end points were death from any cause, 
death from cardiovascular cause, and first hospitalization due 
to cardiovascular events.
The mean follow-up period was 21 months. The pri-
mary composite outcome (incidence of hospitalization due 
to cardiovascular events or death) was significantly lower 
in patients receiving dronedarone as compared to those 
receiving placebo (HR 0.76, 95% CI 0.69–0.84, P , 0.001; 
Table 4). This outcome appeared to be mainly driven by a 
lower risk of hospitalization for cardiovascular events and, in 
particular, for AF (675 cases in the dronedarone group versus 
859 in placebo; HR 0.74, 95% CI 0.67–0.82, P , 0.001). 
No statistical difference for other secondary end points 
was found, except for cardiovascular mortality, which was 
lower in patients receiving dronedarone (HR 0.71, 95% CI 
0.51–0.98, P = 0.03). Treatment was stopped early in 30.2% 
of patients in the dronedarone group as compared with 30.8% 
of those in the placebo group (statistical significance not 
reported). The main reasons for discontinuation were adverse 
events (290 with dronedarone versus 187, P , 0.001): gastro-
intestinal events, increase in serum creatinine, bradycardia, 
and QT-interval prolongation were found to be associated 
with dronedarone (Table 5).
Overall quality of the evidence
The risk of bias was low for the sequence generation process 
and the attrition. No information about the other dimension 
was reported in the paper (Figure 2). ATHENA shows 
that dronedarone reduces the incidence of hospitalization 
due to cardiovascular events or death in patients with 
paroxysmal or persistent AF or flutter who had additional 
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risk factors for major cardiovascular events. It is important 
to underline that the trial has many weaknesses. First of all, 
the difference in the primary composite end point appears to 
be only due to one of its components such as the reduction 
of hospitalization for cardiovascular events. This may have 
been driven by the reduction in hospitalizations for the 
recurrence of AF episodes that could have been treated by 
electrical cardioversion with subsequent early discharge. 
Considering such a short hospital stay (discharge within 
12 hours) as hospitalization may generate a misleading 
outcome evaluation. For this reason we believe that the study 
shows only that dronedarone reduced the recurrence of AF. 
In addition, in the dronedarone group there were significantly 
more women and this difference was not reported at the time 
of publication in The New England Journal of Medicine.27 
For the evaluation of the adverse effects, the length of the 
follow-up can be considered adequate.
DIONYSOS
The Efficacy and Safety of Dronedarone Versus Amiodarone 
for the Maintenance of Sinus Rhythm in Patients With Atrial 
Fibrillation (DIONYSOS) is a phase III, randomized, double 
blind trial that evaluated the efficacy and safety of drone-
darone (400 mg twice a day) versus amiodarone (600 mg/day 
for 28 days and then 200 mg/day for at least 6 months) for 
the maintenance of sinus rhythm in patients with documented 
AF that had lasted more than 72 hours (Tables 2 and 3).23 
The   primary outcome was a composite measure of treatment 
failure, described as the first recurrence of AF including 
unsuccessful electrical cardioversion, no spontaneous con-
version and no electrical cardioversion or premature drug 
discontinuation for lack of efficacy or intolerance. The study 
had also a safety/tolerability end point composed by the 
occurrence of thyroid-, hepatic-, pulmonary-, neurologic-, 
skin-, eye or gastrointestinal-specific events, or premature 
study drug discontinuation for intolerance. Analysis of the 
safety end point without gastrointestinal events (ie, diarrhea, 
nausea, and vomiting) was prespecified. The minimum dura-
tion of follow-up was 6 months.
Five hundred and four subjects were enrolled and the 
two treatment groups were well balanced in terms of demo-
graphic characteristics, cardiovascular history, and co-therapy 
assumed, but in the amiodarone group the AF episode ongo-
ing at the moment of the enrolment had a longer duration 
(54 versus 47.5 days in the dronedarone group, P = 0.0311).
The primary end point at 12 months was in favor of amio-
darone (HR 1.59, 95% CI 1.28–1.98, P # 0.0001; Table 4). 
Although not significantly different, the incidence of the 
main safety end point was reduced in the dronedarone group 
as compared to amiodarone (HR 0.80, 95% CI 0.60–1.07, 
P = 0.129), and there was a statistically significant difference 
in favor of dronedarone when gastrointestinal events were 
excluded from the main safety end point (HR 0.61, 95% CI 
0.44–0.84, P = 0.002; Table 5).
Overall quality of the evidence
The risk of bias of the study cannot be properly evalu-
ated as much information in the reporting was lacking 
(Figure 2). DIONYSOS is a relevant trial because it is 
the only one that compares dronedarone to amiodarone. 
It demonstrates that the supposed improved tolerability 
of dronedarone compared to the known poor tolerability 
of amiodarone does not compensate for its modest antiar-
rhythmic activity. It must be remarked that the efficacy end 
points of the study are not hard outcomes. Furthermore, 
the trial evaluated only combined end points that were 
not   exhaustively described and the differences among the 
definitions of drug discontinuation for lack of efficacy, 
intolerance, or due to any adverse event are not clear. The 
follow-up (6 months) is not long enough to draw relevant 
information about safety.
RCTs including patients in permanent AF
ERATO
The Efficacy and safety of dRonedArone for The cOntrol 
of ventricular rate during atrial fibrillation (ERATO) was a 
phase III, double-blind, randomized controlled trial designed 
to assess the efficacy of dronedarone for ventricular rate 
control in patients with permanent AF. The objective was 
to perform a rate-control strategy.24
Subjects with symptomatic permanent AF, for whom car-
dioversion was appropriate, were enrolled in nine European 
countries. Patients with NYHA class III or IV congestive 
heart failure were excluded (Tables 2 and 3). One hundred 
and eighty-five patients were randomized to receive either 
dronedarone 400 mg twice a day or placebo for 6 months. 
The primary end point was the change in mean ventricular 
rate between baseline and day 14, as assessed by 24-hour 
  electrocardiogram Holter monitoring. A priori defined 
subgroup analysis was programmed, stratifying the primary 
outcome according to concomitant use of other rate-lowering 
drugs. Secondary end points of interest were the changes 
in mean ventricular rate during submaximal and maximal 
exercise between the baseline and day 14 and the changes 
in maximal exercise duration, as assessed by exercise 
  electrocardiogram test.
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In the dronedarone group there was a significantly 
greater reduction of mean 24-hour ventricular rate at day 14 
(–11 beats/minute versus +0.7 beats/minute in the placebo 
group, P , 0.0001) and similar results were observed after 
4 months (Table 4). The efficacy was of greater magnitude 
during submaximal and maximal exercise at day 14. The 
effects of dronedarone rate were additive to those of concomi-
tant rate-controlling drugs. The incidence of adverse events 
was slightly higher in the dronedarone arm (65 events versus 
53, 77% and 60%), although serious adverse cardiovascular 
events were rare and not significantly different between the 
two groups (Table 5).
Overall quality of the evidence
The methodology of the trial is not described in detail and 
consequently we cannot give a proper evaluation of the risk 
of bias (Figure 2). ERATO shows that dronedarone has rate 
control effects in patients with permanent AF. The results 
are coherent to each other and consistent but none of the 
primary or secondary outcomes can be defined as clinically 
relevant. Furthermore, the study was not projected to compare 
dronedarone to traditional rate-control therapies like digoxin, 
calcium antagonists, or beta blockers, so the comparison used 
cannot be considered adequate.
PALLAS
The Permanent Atrial Fibrillation Outcome Study Using 
Dronedarone on Top of Standard Therapy (PALLAS) was 
a double-blind phase III study that evaluated the effect 
of dronedarone (400 mg twice a day) versus placebo on 
major vascular events or unplanned hospitalization for 
cardiovascular causes.25 The study included patients with 
permanent AF or flutter at high risk for vascular events 
(Tables 2 and 3). Patients affected by NYHA class IV 
congestive heart failure were excluded. The two treatment 
groups were well balanced for demographic characteristics 
and cardiovascular history.
The first primary outcome was a composite of stroke, 
myocardial infarction, systemic embolism, or death from 
cardiovascular causes. The second primary outcome was a 
composite of unplanned hospitalization for a cardiovascular 
cause or death.
Ten thousand, eight hundred patients were estimated to be 
enrolled during a 2-year period but the study was   terminated 
for safety reasons after 1 year and the randomization of 
3236 participants (1619 treated with dronedarone and 
1617 in the placebo group). In fact, the first primary out-
come occurred in 43 patients receiving dronedarone and in 
19 receiving placebo (HR 2.29, 95% CI 1.34–3.94; P = 0.002; 
Table 4). There were more deaths for cardiovascular causes 
in the dronedarone group (21 versus 10 in the placebo group, 
HR 2.11, 95% CI 1.00–4.49; P = 0.046), including death from 
arrhythmia in 13 and four patients in each arm, respectively 
(HR 3.26, 95% CI 1.06–10.00; P = 0.03). Twenty-three 
strokes occurred in the dronedarone group and ten in the 
placebo group (HR 2.32, 95% CI 1.11–4.88; P = 0.02). 
Hospitalization for heart failure was observed in 43 patients 
in the dronedarone group and 24 in the placebo group (HR 
1.81; 95% CI 1.10–2.99; P = 0.02). Unplanned hospital-
ization for cardiovascular causes occurred in 113 patients 
receiving dronedarone and 59 patients receiving placebo (HR 
1.97, 95% CI 1.44–2.70, P , 0.001). Study medication was 
permanently discontinued prematurely in 21% of patients 
treated with dronedarone and in 11% of those in the placebo 
group (P , 0.001).
Overall quality of the evidence
There is insufficient information reported in the paper to 
permit evaluation of the risk of bias (Figure 2). PALLAS 
considered clinically relevant end points (stroke, myocardial 
infarction, systemic embolism, or death from cardiovascular 
causes) and produced the important evidence that drone-
darone should not be used in patients with permanent AF 
or flutter at high risk for vascular events. The results of the 
study are coherent to each other and consistent.
RCTs including patients with heart failure
ANDROMEDA
The Antiarrhythmic Trial with Dronedarone in Moderate to 
Severe CHF Evaluating Morbidity Decrease (ANDROM-
EDA) is a phase III trial that evaluated the use of dronedarone 
(400 mg twice a day) versus placebo in hospitalized patients 
with new or worsening heart failure and severe systolic 
  dysfunction heart failure26 (Tables 2 and 3). Consecutive 
adult patients were included.
The trial had a composed primary end point, including 
death from any cause or hospitalization for worsening heart 
failure. Secondary end points were death from any cause, 
hospitalization for worsening heart failure, occurrence of AF 
or atrial flutter, death from arrhythmia, or sudden death. The 
overall percentage of participants with a history of AF/  flutter 
was 38%, while the percentage of subjects in AF at the 
baseline was 25% (23.2% in the dronedarone and 26.8% in 
the placebo group).
A sample size of 1000 patients had been planned, but after 
the inclusion of 627 patients (310 in the dronedarone group 
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and 317 in the placebo group), the trial was prematurely 
stopped for an excess of deaths in patients taking drone-
darone (25 versus 12 in the placebo group, HR 2.13, 95% CI 
1.07–4.25, P = 0.03). The primary composite outcome was in 
the same direction as mortality but did not reach a statistical 
difference (HR 1.38, 95% CI 0.92–2.09; Table 4). Deaths in 
the dronedarone group were mainly related to progressive 
heart failure, arrhythmia, or sudden death. No significant dif-
ference in mortality between the two groups was observed in 
the 6-month follow-up after discontinuation of the treatment 
(HR 1.13, 95% CI 0.73–1.74, P = 0.60) and no significant 
difference was reported for other adverse events except for 
a higher number of patients with increased creatinine levels 
in the dronedarone group (Table 5).
Overall quality of the evidence
The risk of bias in the study was low overall but no informa-
tion about allocation concealment and blinding of outcome 
assessment was reported (Figure 2). ANDROMEDA is the 
only trial using hard and clinically relevant end points to test 
the effect of dronedarone in patients with severe congestive 
heart failure for whom AF was not an inclusion criterion. 
Considering that amiodarone is one of the few antiarrhyth-
mic drugs that does not increase mortality in patients with 
moderate to severe left ventricular dysfunction, the study 
was projected in the hypothesis that dronedarone would have 
improved prognosis in these patients. On the contrary, the 
results show that dronedarone should not be used in patients 
with severe congestive heart failure, with or without AF.
Discussion
Summary of evidence
The major findings have to be defined in the different 
populations studied in the various RCTs analyzed and 
are the following: (1) compared to placebo, dronedarone 
reduces the recurrence of AF leading to a lower incidence 
of hospitalization in patients with nonpermanent AF; 
(2) dronedarone is less effective than amiodarone for the 
prevention of recurrent AF; (3) in patients with heart failure 
or with permanent AF and a high risk for cardiovascular 
events dronedarone is associated with increased mortality.
In the management of AF either a “rhythm-control” or 
“rate-control” strategy can be chosen; to date the superiority of 
one strategy over the other has not been demonstrated.9–11.
In the “rhythm-control” option, the goal is to prevent 
AF recurrences in patients with persistent symptoms despite 
adequate rate-control. The DAFNE and EURIDIS/ADONIS 
studies evaluated the efficacy of dronedarone in reducing 
recurrences in subjects with nonpermanent AF. The trials 
demonstrated that dronedarone is efficacious when com-
pared to placebo. These results are consistent with those of 
a recent meta-analysis that showed that antiarrhythmics of 
different pharmacological classes (class IA, class IC, and 
class III drugs) were efficacious in controlling the recur-
rences of AF; these occurred 20% to 50% less than in patients 
not receiving antiarrhythmics.12 However, the efficacy of 
antiarrhythmic drugs is limited, as demonstrated by the fact 
that AF still recurred in 42% to 67% of treated patients in 
1 year.12   Similarly, in the EURIDIS/ADONIS trials, the 64% 
of subjects treated with dronedarone experienced recurrences 
of AF.
The ATHENA trial showed that in comparison to 
placebo, dronedarone resulted in a statistically significant 
reduction in the primary composite end point of time to first 
cardiovascular hospitalization or death from any cause in 
patients with nonpermanent AF. It is important to remark 
that the primary end point was mainly driven by reduction 
of AF recurrences, as were the DAFNE and EURIDIS/
ADONIS results.
In an indirect comparison meta-analysis, Piccini et al 
evaluated eight trials (four trials evaluating amiodarone 
  versus placebo, four dronedarone versus placebo),   finding 
that amiodarone was superior to dronedarone in the 
  prevention of recurrent AF (OR 0.16, 95% CI 0.06–0.42, 
P , 0.001).28 These data appear to support the results of the 
direct comparison in the DIONYSOS trial that demonstrated 
the superiority of amiodarone over dronedarone in the pre-
vention of AF recurrences in subjects with nonpermanent 
AF (OR 0.44, 95% CI: 0.30–0.64).28 Moreover, in a recent 
meta-analysis of studies of enrolled patients who recovered 
sinus rhythm after AF, Lafuente-Lafuente et al showed that 
the most efficacious drug in preventing recurrences of AF 
was amiodarone and the related number needed to treat to 
prevent one event in 1 year was three.12
Dronedarone was developed to reduce the adverse events 
associated with antiarrhythmic class III treatment. It was 
demonstrated that amiodarone had a greater incidence of 
adverse events leading to discontinuation of therapy than 
placebo.12,28 In the comparative DIONYSOS trial, it is 
uncertain whether dronedarone is associated with a lower rate 
of discontinuations than amiodarone, as all the confidence 
intervals of the direct comparison cross 1. It must be noted 
that the safety results of DIONYSOS are difficult to interpret 
due to the short duration (6 months) of the trial, taking into 
account that the toxicities of amiodarone may arise after 
years of chronic therapy. In studies that enrolled patients 
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with paroxysmal or persistent AF, mortality was evaluated 
in the ATHENA trial only. In the latter, cardiovascular 
mortality was significantly lower in patients receiving 
dronedarone compared to those receiving placebo; it is 
difficult to comment on the data taking into account that 
the mortality was a secondary end point of the study. The 
results should be confirmed in an ad hoc designed study. The 
meta-analysis of Lafuente-Lafuente et al demonstrated that 
mortality was not modified by antiarrhythmic drugs, except 
for disopyramide and quinidine that were associated with 
increased mortality.12
Considering patients with permanent AF and the choice 
of “rate-control” therapy, dronedarone was evaluated in 
the ERATO and PALLAS trials. The ERATO trial showed 
that dronedarone has rate-control effects in patients with 
permanent AF; considering the surrogate outcomes of the 
trials, data were not sufficient to recommend dronedarone 
for rate control. The PALLAS trial considered clinically 
relevant outcomes and the study was stopped early since 
strokes, myocardial infarctions, systemic embolisms, or 
deaths from cardiovascular causes were significantly more 
frequent in subjects treated with dronedarone as compared 
to placebo. These results indicate that dronedarone should 
not be prescribed in subjects with permanent AF and a high 
risk of vascular events.
The ANDROMEDA trial intended to study subjects with 
new symptomatic heart failure (more than NYHA functional 
class II) and severe left ventricular systolic dysfunction 
(#35%); a not insignificant proportion of patients in the study 
had AF. It was terminated prematurely because of excess 
mortality among patients in the dronedarone group, demon-
strating that the drug should not be used in ANDROMEDA-
like patients, with or without AF.
It is difficult to determine the reasons for the excess 
  mortality in PALLAS and in ANDROMEDA trials. The 
patients included had risk factors for major vascular events, 
but the risk profile was not considerably different from that 
observed in ATHENA trial where the results were com-
pletely different. Considering the results from PALLAS and 
ANDROMEDA, safety concerns about dronedarone are 
increasing. Recently, the US Food and Drug Administration 
reported cases of hepatocellular liver injury and hepatic 
failure in patients treated with dronedarone, including two 
postmarketing reports of acute hepatic failure requiring 
transplantation.29
The clinical practice guidelines provide a summary of 
the most current literature and recommendations for the 
prevention and management of conditions based on current 
scientific evidence. The ACCF/AHA and ESC guidelines do 
not give identical recommendations for non-permanent AF 
management and are dissimilar for the indications about the 
use of dronedarone (Table 1). Cardiovascular guidelines on 
the same clinical question by different expert groups often 
disagree,30 and the latter can be a barrier to acceptance of 
guidelines. However, disagreement among recommendations 
is not necessarily a sign of poor quality, as weak evidence 
may lead to discordant conclusions. Conflict of interest 
can also play a role especially in the cardiovascular field. 
It has been reported that half of the authors and reviewers 
of cardiovascular clinical practice guidelines have at least 
one conflict of interest.31 In the ACCF/AHA guidelines 
committee 4/12 panelists reported a conflict of interest with 
the manufacturer of dronedarone, although among them three 
refused to vote on recommendations regarding the use of the 
drug; ten of 25 authors of ESC guidelines reported conflict 
of interest with the manufacturer of dronedarone. We believe 
that disclosure of conflicts of interest allows the professional 
integrity of guideline group members to be assessed. 
Moreover, instruments to assess the quality of clinical 
practice guidelines are pivotal. The Appraisal of Guidelines 
for Research and Evaluation (AGREE) instrument32 provides 
a validated, internationally agreed framework for evaluating 
both the quality of the reporting and the quality of some 
aspects of recommendations. Its application can be the 
first step toward quality improvement and protection from 
financial and nonfinancial conflicts of interest.
In the clinical scenario presented, the patient had 
persistent AF and structural heart disease; the subject could 
be considered an ATHENA-like patient, but, after the 
considerations made, we believe that the quality and strength 
of the evidence for prescribing dronedarone are not sufficient. 
We would not have prescribed the drug.
Study limitations
Our analysis was restricted to RCTs. It is well known 
that these trials minimize bias, but concern about external 
validity can arise since they may not reflect patients treated 
in general clinical practice. Furthermore, in many of the 
included trials, information about the methodology used 
was not reported (methods of sequence generation and 
allocation concealment, strategies to guarantee blindness, 
etc) so we were not able to evaluate their internal quality. 
The follow-up of the studies was short in duration, while 
for properly evaluating the toxicity of dronedarone more 
long-term data are needed. Finally, the manufacturer of 
dronedarone sponsored all the trials.
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Conclusion
In subjects with AF, several randomized controlled trials have 
evaluated the efficacy and the safety of dronedarone versus 
placebo and one compared dronedarone with amiodarone. 
The results of the studies suggest that dronedarone should 
be avoided in patients with permanent AF and a high risk 
for cardiovascular events or severe congestive heart failure. 
In subjects with paroxysmal or persistent AF, dronedarone, 
like most antiarrhythmic drugs, reduces the recurrence of 
AF compared to placebo but relapse rates in the first year of 
therapy are high. Furthermore, dronedarone showed to be 
less effective than amiodarone. Considering the data derived 
from the trials that were terminated prematurely because 
of safety concerns and the absence of studies showing the 
superiority of dronedarone over the other antarrhythmics, 
further investigations are needed before supporting the use of 
dronedarone for the maintainance of sinus rhythm in patients 
with atrial fibrillation.
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